ApiJect Systems Corp. positioned itself as the company that would make the difference between a stumbling rollout and delivery of lifesaving vaccines.
Moderna didn't respond to a request for comment, and Johnson & Johnson declined to comment.
ApiJect spokesperson Steve Hofman said the land in North Carolina has been cleared and graded for construction.
The Trump administration also approved a Defense Production Act loan for ApiJect of up to $590 million.
In all, the administration awarded the company nearly $1.3 billion in loans and contracts last year.
The FDA would have to determine that storing vaccine in ApiJect's syringe didn't cause problems, such as corroding the syringe's plastic.
And ApiJect syringes could still play a key role in getting vaccines to Americans, especially if booster shots are needed. »